Download PDF
Fortschr Neurol Psychiatr 2008; 76(7): 421-428
DOI: 10.1055/s-2008-1038220
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Pharmakologische Therapieoptionen zur Prävention des Alkoholrückfalls

Pharmacological Treatment Options for Prevention of Alcohol RelapseA.  Heberlein1 , S.  Bleich1 , J.  Kornhuber1 , T.  Hillemacher1
  • 1Psychiatrische und Psychotherapeutische Klinik, Universitätsklinikum Erlangen
Further Information

Publication History

Publication Date:
04 July 2008 (online)

    Permissions and Reprints

Zusammenfassung

Die Intensität des Suchtdrucks (Craving) wird maßgeblich mit dem Rückfallrisiko der Alkoholabhängigkeit in Zusammenhang gebracht. Es wird angenommen, dass zumindest 3 Gruppen des Craving unterscheidbar sind, denen auf neuronaler Ebene Veränderungen in unterschiedlichen Neurotransmittersystemen zugrunde liegen. Momentan sind in Deutschland die Substanzen Acamprosat und Disulfiram zur Rückfallprophylaxe der Alkoholabhängigkeit zugelassen. Im Rahmen von Therapieversuchen ist auch eine Anwendung von Naltrexon möglich. Aktuelle Studienergebnisse zeigen jedoch, dass diese Substanzen nicht bei allen Patienten gleichermaßen wirksam sind. Substanzen, die spezifisch auf die zugrunde liegenden Neurotransmitterveränderungen wirken, könnten hypothetisch die Wirksamkeit der medikamentösen Alkoholrückfallprophylaxe bei bestimmten Personengruppen erhöhen. Deswegen werden aktuell weitere Substanzgruppen auf eine mögliche Wirksamkeit in der Alkoholrückfallprophylaxe untersucht. Substanzen, die in präklinischen oder ersten klinischen Studien Wirksamkeit in der Alkoholrückfallprävention gezeigt haben, sind Baclofen, Topiramat, Odansetron, Rimonabant und Memantin.

Abstract

Many studies address the neurobiological mechanisms of alcohol craving. The study results obtained so far show that there may be at least three subtypes of craving, which may be linked to changes in different neurotransmitter systems. Actually in Germany acamprosate and disulfiram are approved for clinical use for the prevention of alcohol relapse. Also off-label therapy with naltrexone is possible. However studies show that these substances are not effective in all patients. In the light of hypothetical changes in different neurotransmitter systems, subtype specific therapy may be necessary for successful prevention of alcohol relapse. Therefore new therapy options are needed in order to treat alcohol dependent persons. Substances that seem to have efficacy in preclinical or preliminary clinical studies are baclofen, topiramate, odansetron, rimonabant and memantine.

Schlüsselwörter

Alkoholabhängigkeit - Alkoholentzug - Rückfallprävention - Craving - Pharmakotherapie

Key words

alcohol addiction - alcohol withdrawal - craving - relapse prevention - pharmacotherapy

Literatur

  • 1 Mann K. Neue ärztliche Aufgaben bei Alkoholproblemen.  Dtsch Ärztebl. 2002;  99 632-644
    Google Scholar
  • 2 Diehl A, Mann K. Pharmakologische Rückfallprävention bei Alkohol und Tabakabhängigkeit.  Internist (Berl). 2007;  48 79-84, 86 – 88
    Google Scholar
  • 3 Kiefer F, Mann K. Diagnostik und Therapie der Alkoholabhängigkeit.  Fortschr Neurol Psychiatr. 2007;  75 33-46
    Google Scholar
  • 4 Addolorato G, Abenavoli L, Leggio L. et al . How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review.  Neuropsychobiology. 2005;  51 59-66
    Google Scholar
  • 5 Hillemacher T, Kornhuber J, Bleich S. Neurobiologische Mechanismen und Pharmakologische Behandlungsansätze des Alkohol-Craving.  Fortschr Neurol Psychiatr. 2007;  75 26-32
    Google Scholar
  • 6 Bottlender M, Soyka M. Impact of craving on alcohol relapse during, and 12 months following, outpatient treatment.  Alcohol Alcohol. 2004;  39 357-361
    Google Scholar
  • 7 Bleich S, Sperling W, Wiltfang J. et al . Exzitatorische Neurotransmission bei chronischem Alkoholismus.  Fortschr Neurol Psychiatr. 2003;  71 Suppl 1 S36-44
    Google Scholar
  • 8 Kiefer F, Mann K. New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence.  Eur J Pharmacol. 2005;  526 163-171
    Google Scholar
  • 9 Tsai G E, Ragan P, Chang R. et al . Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal.  Am J Psychiatry. 1998;  155 726-732
    Google Scholar
  • 10 Heinz A, Schäfer M, Higley J D. et al . Neurobiological correlates of the disposition and maintenance of alcoholism.  Pharmacopsychiatry. 2003;  36 Suppl 3 S255-258
    Google Scholar
  • 11 Fadda F, Mosca E, Meloni R. et al . Ethanol-stress interaction on dopamine metabolism in the medial prefrontal cortex.  Alcohol Drug Res. 1985;  6 449-454
    Google Scholar
  • 12 Davis W M, Smith S G, Werner T E. Noradrenergic role in the self-administration of ethanol.  Pharmacol Biochem Behav. 1978;  9 369-374
    Google Scholar
  • 13 Weiss F, Porrino L J. Behavioral neurobiology of alcohol addiction: recent advances and challenges.  J Neurosci. 2002;  22 3332-3337
    Google Scholar
  • 14 Ulm R R, Volpicelli J R, Volpicelli L A. Opiates and alcohol self-administration in animals.  J Clin Psychiatry. 1995;  56 Suppl 7 5-14
    Google Scholar
  • 15 Bönsch D, Reulbach U, Bayerlein K. et al . Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism.  Biol Psychiatry. 2004;  56 984-986
    Google Scholar
  • 16 Bönsch D, Greifenberg V, Bayerlein K. et al . Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving.  Alcohol Clin Exp Res. 2005;  29 763-765
    Google Scholar
  • 17 Bönsch D, Lederer T, Reulbach U. et al . Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence.  Hum Mol Genet. 2005;  14 967-971
    Google Scholar
  • 18 Hillemacher T, Bleich S, Frieling H. et al . Evidence of an association of leptin serum levels and craving in alcohol dependence.  Psychoneuroendocrinology. 2007;  32 87-90
    Google Scholar
  • 19 Hillemacher T, Kraus T, Rauh J. et al . Role of appetite-regulating peptides in alcohol craving: an analysis in respect to subtypes and different consumption patterns in alcoholism.  Alcohol Clin Exp Res. 2007;  31 950-954
    Google Scholar
  • 20 Hillemacher T, Bayerlein K, Reulbach U. et al . Influence of beer, wine and spirits consumption on craving.  Addict Biol. 2005;  10 181-186
    Google Scholar
  • 21 Hillemacher T, Bayerlein K, Wilhelm J. et al . Volume intake and craving in alcohol withdrawal.  Alcohol Alcohol. 2006;  41 61-65
    Google Scholar
  • 22 Bayerlein K, Hillemacher T, Reulbach U. et al . Alcoholism-associated hyperhomocysteinemia and previous withdrawal seizures.  Biol Psychiatry. 2005;  57 1590-1593
    Google Scholar
  • 23 Hillemacher T, Frieling H, Bayerlein K. et al . Biological markers to predict previous alcohol withdrawal seizures: a risk assessment.  J Neural Transm. 2007;  114 151-154
    Google Scholar
  • 24 Bleich S, Degner D, Sperling W. et al . Homocysteine as a neurotoxin in chronic alcoholism.  Prog Neuropsychopharmacol Biol Psychiatry. 2004;  28 453-464
    Google Scholar
  • 25 Hillemacher T, Reulbach U, Bayerlein K. et al . Plasma homocysteine concentrations do not influence craving in alcohol withdrawal.  Alcohol. 2004;  34 211-215
    Google Scholar
  • 26 Verheul R, Brink W van den, Geerlings P. A three-pathway psychobiological model of craving for alcohol.  Alcohol Alcohol. 1999;  34 197-222
    Google Scholar
  • 27 Heinz A, Löber S, Georgi A. et al . Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake.  Alcohol Alcohol. 2003;  38 35-39
    Google Scholar
  • 28 Kiefer F, Helwig H, Tarnaske T. et al . Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.  Eur Addict Res. 2005;  11 83-91
    Google Scholar
  • 29 Kranzler H R, Kirk J van. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.  Alcohol Clin Exp Res. 2001;  25 1335-1341
    Google Scholar
  • 30 Kranzler H R, Koob G, Gastfriend D R. et al . Advances in the pharmacotherapy of alcoholism: challenging misconceptions.  Alcohol Clin Exp Res. 2006;  30 272-281
    Google Scholar
  • 31 Garbutt J C, West S L, Carey T S. et al . Pharmacological treatment of alcohol dependence: a review of the evidence.  Jama. 1999;  281 1318-1325
    Google Scholar
  • 32 Ehrenreich H, Mangholz A, Schmitt M. et al . OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approach.  Eur Arch Psychiatry Clin Neurosci. 1997;  247 51-54
    Google Scholar
  • 33 Krampe H, Stawicki S, Wagner T. et al . Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome.  Alcohol Clin Exp Res. 2006;  30 86-95
    Google Scholar
  • 34 Fuller R K, Branchey L, Brightwell D R. et al . Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.  Jama. 1986;  256 1449-1455
    Google Scholar
  • 35 Bottlender M, Köhler J, Soyka M. Effektivität psychosozialer Behandlungsmethoden zur medizinischen Rehabilitation alkoholabhängiger Patienten.  Fortschr Neurol Psychiatr. 2006;  74 19-31
    Google Scholar
  • 36 Rammes G, Mahal B, Putzke J. et al . The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801.  Neuropharmacology. 2001;  40 749-760
    Google Scholar
  • 37 Gewiss M, Heidbreder C, Opsomer L. et al . Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour.  Alcohol Alcohol. 1991;  26 129-137
    Google Scholar
  • 38 Mann K, Lehert P, Morgan M Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.  Alcohol Clin Exp Res. 2004;  28 51-63
    Google Scholar
  • 39 Lesch O M, Riegler A, Gutierrez K. et al . The European acamprosate trials: conclusions for research and therapy.  J Biomed Sci. 2001;  8 89-95
    Google Scholar
  • 40 Chick J, Anton R, Checinski K. et al . A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.  Alcohol Alcohol. 2000;  35 587-593
    Google Scholar
  • 41 Volpicelli J R, Alterman A I, Hayashida M. et al . Naltrexone in the treatment of alcohol dependence.  Arch Gen Psychiatry. 1992;  49 876-880
    Google Scholar
  • 42 Volpicelli J R, Rhines K C, Rhines J S. et al . Naltrexone and alcohol dependence. Role of subject compliance.  Arch Gen Psychiatry. 1997;  54 737-742
    Google Scholar
  • 43 Gastpar M, Bonnet U, Boning J. et al . Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.  J Clin Psychopharmacol. 2002;  22 592-598
    Google Scholar
  • 44 Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials.  Int J Neuropsychopharmacol. 2005;  8 267-280
    Google Scholar
  • 45 Krystal J H, Cramer J A, Krol W F. et al . Naltrexone in the treatment of alcohol dependence.  N Engl J Med. 2001;  345 1734-1739
    Google Scholar
  • 46 Kiefer F, Jimenez-Arriero M A, Klein O. et al . Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.  Addict Biol. 2007;  13 124-129
    Google Scholar
  • 47 Volpicelli J R, Clay K L, Watson N T. et al . Naltrexone in the treatment of alcoholism: predicting response to naltrexone.  J Clin Psychiatry. 1995;  56 Suppl 7 39-44
    Google Scholar
  • 48 Ray L A, Hutchison K E. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.  Alcohol Clin Exp Res. 2004;  28 1789-1795
    Google Scholar
  • 49 Oslin D W, Berrettini W, Kranzler H R. et al . A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.  Neuropsychopharmacology. 2003;  28 1546-1552
    Google Scholar
  • 50 Garbutt J C, Kranzler H R, O'Malley S S. et al . Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.  Jama. 2005;  293 1617-1625
    Google Scholar
  • 51 Monti P M, Rohsenow D J, Swift R M. et al . Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.  Alcohol Clin Exp Res. 2001;  25 1634-1647
    Google Scholar
  • 52 Cornelius J R, Salloum I M, Ehler J G. et al . Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial.  Arch Gen Psychiatry. 1997;  54 700-705
    Google Scholar
  • 53 Pettinati H M, Volpicelli J R, Luck G. et al . Double-blind clinical trial of sertraline treatment for alcohol dependence.  J Clin Psychopharmacol. 2001;  21 143-153
    Google Scholar
  • 54 Tiihonen J, Ryynanen O P, Kauhanen J. et al . Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study.  Pharmacopsychiatry. 1996;  29 27-29
    Google Scholar
  • 55 Naranjo C A, Bremner K E, Lanctot K L. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems.  Addiction. 1995;  90 87-99
    Google Scholar
  • 56 Johnson B A, Jasinski D R, Galloway G P. et al . Ritanserin in the treatment of alcohol dependence – a multi-center clinical trial. Ritanserin Study Group.  Psychopharmacology (Berl). 1996;  128 206-215
    Google Scholar
  • 57 Wiesbeck G A, Weijers H G, Chick J. et al . Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group.  Alcohol Clin Exp Res. 1999;  23 230-235
    Google Scholar
  • 58 Bruno F. Buspirone in the treatment of alcoholic patients.  Psychopathology. 1989;  22 Suppl 1 49-59
    Google Scholar
  • 59 Kranzler H R, Modesto-Lowe V, Kirk J van. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.  Neuropsychopharmacology. 2000;  22 493-503
    Google Scholar
  • 60 Johnson B A, Campling G M, Griffiths P. et al . Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers.  Psychopharmacology (Berl). 1993;  112 142-144
    Google Scholar
  • 61 Sellers E M, Toneatto T, Romach M K. et al . Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence.  Alcohol Clin Exp Res. 1994;  18 879-885
    Google Scholar
  • 62 Johnson B A, Roache J D, Javors M A. et al . Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.  Jama. 2000;  284 963-971
    Google Scholar
  • 63 Kranzler H R, Pierucci-Lagha A, Feinn R. et al . Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study.  Alcohol Clin Exp Res. 2003;  27 1150-1155
    Google Scholar
  • 64 Johnson B A, Cloninger C R, Roache J D. et al . Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population.  Am J Addict. 2000;  9 17-27
    Google Scholar
  • 65 Johnson B A, Ait-Daoud N, Prihoda T J. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.  Alcohol Clin Exp Res. 2000;  24 737-742
    Google Scholar
  • 66 Ait-Daoud N, Johnson B A, Prihoda T J. et al . Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.  Psychopharmacology (Berl). 2001;  154 23-27
    Google Scholar
  • 67 Dorus W, Ostrow D G, Anton R. et al . Lithium treatment of depressed and nondepressed alcoholics.  Jama. 1989;  262 1646-1652
    Google Scholar
  • 68 Mueller T I, Stout R L, Rudden S. et al . A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence.  Alcohol Clin Exp Res. 1997;  21 86-92
    Google Scholar
  • 69 Brady K T, Myrick H, Henderson S. et al . The use of divalproex in alcohol relapse prevention: a pilot study.  Drug Alcohol Depend. 2002;  67 323-330
    Google Scholar
  • 70 Salloum I M, Cornelius J R, Daley D C. et al . Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.  Arch Gen Psychiatry. 2005;  62 37-45
    Google Scholar
  • 71 Claudino A M, de Oliveira I R, Appolinario J C. et al . Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder.  J Clin Psychiatry. 2007;  68 1324-1332
    Google Scholar
  • 72 McElroy S L, Hudson J I, Capece J A. et al . Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study.  Biol Psychiatry. 2007;  61 1039-1048
    Google Scholar
  • 73 Ait-Daoud N, Malcolm Jr R J, Johnson B A. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants.  Addict Behav. 2006;  31 1628-1649
    Google Scholar
  • 74 Johnson B A, Swift R M, Ait-Daoud N. et al . Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics.  Alcohol Clin Exp Res. 2004;  28 295-301
    Google Scholar
  • 75 Johnson B A. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence?.  Addict Behav. 2004;  29 1465-1479
    Google Scholar
  • 76 Johnson B A, Ait-Daoud N, Bowden C L. et al . Oral topiramate for treatment of alcohol dependence: a randomised controlled trial.  Lancet. 2003;  361 1677-1685
    Google Scholar
  • 77 Miranda Jr R, Mackillop J, Monti P M. et al . Effects of Topiramate on Urge to Drink and the Subjective Effects of Alcohol: A Preliminary Laboratory Study.  Alcohol Clin Exp Res. 2008;  block
    Google Scholar
  • 78 Gong W, Neill D B, Justice Jr J B. GABAergic modulation of ventral pallidal dopamine release studied by in vivo microdialysis in the freely moving rat.  Synapse. 1998;  29 406-412
    Google Scholar
  • 79 Kushner S A, Dewey S L, Kornetsky C. Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds.  Psychopharmacology (Berl). 1997;  133 383-388
    Google Scholar
  • 80 Spanagel R. Die Rolle des glutamatergen Systems bei Alkoholsucht.  Fortschr Neurol Psychiatr. 2003;  71 Suppl 1 S33-35
    Google Scholar
  • 81 Römer K D, Bleich S, Kornhuber J. Glutamat – Ein Transmitter im Spannungsfeld zwischen Toxin und Trophin.  Fortschr Neurol Psychiatr. 2003;  71 Suppl 1 S3-9
    Google Scholar
  • 82 Colombo G, Agabio R, Carai M A. et al . Ability of baclofen in reducing alcohol intake and withdrawal severity: I – Preclinical evidence.  Alcohol Clin Exp Res. 2000;  24 58-66
    Google Scholar
  • 83 Colombo G, Serra S, Brunetti G. et al . Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats.  Drug Alcohol Depend. 2003;  70 105-108
    Google Scholar
  • 84 Colombo G, Serra S, Vacca G. et al . Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212–2 in alcohol-preferring rats.  Eur J Pharmacol. 2004;  492 189-193
    Google Scholar
  • 85 Colombo G, Agabio R, Lobina C. et al . Stimulation of locomotor activity by voluntarily consumed ethanol in Sardinian alcohol-preferring rats.  Eur J Pharmacol. 1998;  357 109-113
    Google Scholar
  • 86 Chester J A, Cunningham C L. Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice.  Pharmacol Biochem Behav. 1999;  63 325-331
    Google Scholar
  • 87 Colombo G, Vacca G, Serra S. et al . Baclofen suppresses motivation to consume alcohol in rats.  Psychopharmacology (Berl). 2003;  167 221-224
    Google Scholar
  • 88 Anstrom K K, Cromwell H C, Markowski T. et al . Effect of baclofen on alcohol and sucrose self-administration in rats.  Alcohol Clin Exp Res. 2003;  27 900-908
    Google Scholar
  • 89 Liang J H, Chen F, Krstew E. et al . The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats.  Neuropharmacology. 2006;  50 632-639
    Google Scholar
  • 90 Maccioni P, Serra S, Vacca G. et al . Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats.  Alcohol. 2005;  36 161-168
    Google Scholar
  • 91 Addolorato G, Caputo F, Capristo E. et al . Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study.  Alcohol Alcohol. 2002;  37 504-508
    Google Scholar
  • 92 Flannery B A, Garbutt J C, Cody M W. et al . Baclofen for alcohol dependence: a preliminary open-label study.  Alcohol Clin Exp Res. 2004;  28 1517-1523
    Google Scholar
  • 93 Addolorato G, Caputo F, Capristo E. et al . Ability of baclofen in reducing alcohol craving and intake: II – Preliminary clinical evidence.  Alcohol Clin Exp Res. 2000;  24 67-71
    Google Scholar
  • 94 Addolorato G, Caputo F, Capristo E. et al . Rapid suppression of alcohol withdrawal syndrome by baclofen.  Am J Med. 2002;  112 226-229
    Google Scholar
  • 95 Addolorato G, Leggio L, Abenavoli L. et al . Suppression of alcohol delirium tremens by baclofen administration: a case report.  Clin Neuropharmacol. 2003;  26 258-262
    Google Scholar
  • 96 Addolorato G, Leggio L, Abenavoli L. et al . Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam.  Am J Med. 2006;  119 276 e13-18
    Google Scholar
  • 97 Addolorato G, Leggio L, Ferrulli A. et al . Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.  Lancet. 2007;  370 1915-1922
    Google Scholar
  • 98 Bleich S, Römer K, Wiltfang J. et al . Glutamate and the glutamate receptor system: a target for drug action.  Int J Geriatr Psychiatry. 2003;  18 S33-40
    Google Scholar
  • 99 Kornhuber J, Bormann J, Retz W. et al . Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex.  Eur J Pharmacol. 1989;  166 589-590
    Google Scholar
  • 100 Krystal J H, Karper L P, Seibyl J P. et al . Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.  Arch Gen Psychiatry. 1994;  51 199-214
    Google Scholar
  • 101 Bienkowski P, Krzascik P, Koros E. et al . Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures in the rat.  Eur J Pharmacol. 2001;  413 81-89
    Google Scholar
  • 102 Kotlinska J. NMDA antagonists inhibit the development of ethanol dependence in rats.  Pol J Pharmacol. 2001;  53 47-50
    Google Scholar
  • 103 Hölter S M, Danysz W, Spanagel R. Evidence for alcohol anti-craving properties of memantine.  Eur J Pharmacol. 1996;  314 R1-2
    Google Scholar
  • 104 Bisaga A, Evans S M. Acute effects of memantine in combination with alcohol in moderate drinkers.  Psychopharmacology (Berl). 2004;  172 16-24
    Google Scholar
  • 105 Krupitsky E M, Neznanova O, Masalov D. et al . Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients.  Am J Psychiatry. 2007;  164 519-523
    Google Scholar
  • 106 Evans S M, Levin F R, Brooks D J. et al . A pilot double-blind treatment trial of memantine for alcohol dependence.  Alcohol Clin Exp Res. 2007;  31 775-782
    Google Scholar
  • 107 Basavarajappa B S, Hungund B L. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview.  Prostaglandins Leukot Essent Fatty Acids. 2002;  66 287-299
    Google Scholar
  • 108 Fattore L, Fadda P, Fratta W. Endocannabinoid regulation of relapse mechanisms.  Pharmacol Res. 2007;  56 418-427
    Google Scholar
  • 109 Rimondini R, Sommer W, Heilig M. A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication.  J Stud Alcohol. 2003;  64 445-449
    Google Scholar
  • 110 Cippitelli A, Bilbao A, Hansson A C. et al . Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats.  Eur J Neurosci. 2005;  21 2243-2251
    Google Scholar
  • 111 Basavarajappa B S, Cooper T B, Hungund B L. Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane.  Brain Res. 1998;  793 212-218
    Google Scholar
  • 112 Basavarajappa B S, Hungund B L. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells.  J Neurochem. 1999;  72 522-528
    Google Scholar
  • 113 Wang L, Liu J, Harvey-White J. et al . Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.  Proc Natl Acad Sci USA. 2003;  100 1393-1398
    Google Scholar
  • 114 Hungund B L, Szakall I, Adam A. et al . Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens.  J Neurochem. 2003;  84 698-704
    Google Scholar
  • 115 Colombo G, Orru A, Lai P. et al . The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.  Mol Neurobiol. 2007;  36 102-112
    Google Scholar
  • 116 Lallemand F, De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats.  Alcohol. 2006;  39 125-134
    Google Scholar
  • 117 Litten R Z, Fertig J, Mattson M. et al . Development of medications for alcohol use disorders: recent advances and ongoing challenges.  Expert Opin Emerg Drugs. 2005;  10 323-343
    Google Scholar

Dr. med. Annemarie Heberlein

Psychiatrische und Psychotherapeutische Klinik, Universitätsklinikum Erlangen

Schwabachanlage 6

91054 Erlangen

Email: annemarie.heberlein@uk-erlangen.de

      >